May
2003

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.

Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP
J Pain Symptom Manage 2003;25(6):512-518.
NATA Rating :
Review by :
NATA Review

A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly replaced now with the once weekly dose, starting at 40,000 U SQ.

– David H. Henry